Sector News

Merck clears major hurdle to Sigma-Aldrich takeover

October 22, 2015
Life sciences

(Reuters) – Merck has cleared a major anti-trust hurdle to its planned $17 billion (11 billion pound) acquisition of Sigma-Aldrich with the latter’s agreed sale of assets to Honeywell , the German drugmaker said on Tuesday.

Merck said U.S. life science company Sigma-Aldrich would sell parts of its solvents and inorganics business in Europe to industrial group Honeywell, which said separately it would pay about 105 million euros ($119 million) for the assets.

“This is another key step towards completing the acquisition of Sigma-Aldrich,” Merck executive board member Bernd Reckmann said in a statement on Tuesday.

Merck said it still expected to close the acquisition of Sigma-Aldrich, its biggest takeover, by the end of November.

The European Commission has to approve the asset sale to Honeywell in order for Merck to close the bigger transaction.

Merck aims to boost its lab-supplies business with the all-cash deal which was agreed more than a year ago.

(Reporting by Georgina Prodhan; editing by Jason Neely)

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.